Literature DB >> 30718929

Sodium Zirconium Cyclosilicate.

Terri L Levien1, Danial E Baker1.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Entities:  

Year:  2018        PMID： 30718929      PMCID： PMC6333952          DOI： 10.1177/0018578718817470

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  12 in total

Review 1.  Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.

Authors:  Biff F Palmer
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

Review 2.  Pathogenesis, diagnosis and management of hyperkalemia.

Authors:  Anja Lehnhardt; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

3.  A new era for the treatment of hyperkalemia?

Authors:  Julie R Ingelfinger
Journal:  N Engl J Med       Date:  2014-11-21       Impact factor: 91.245

4.  Sodium zirconium cyclosilicate in hyperkalemia.

Authors:  David K Packham; Henrik S Rasmussen; Philip T Lavin; Mohamed A El-Shahawy; Simon D Roger; Geoffrey Block; Wajeh Qunibi; Pablo Pergola; Bhupinder Singh
Journal:  N Engl J Med       Date:  2014-11-21       Impact factor: 91.245

5.  Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

Authors:  Matthew R Weir; George L Bakris; David A Bushinsky; Martha R Mayo; Dahlia Garza; Yuri Stasiv; Janet Wittes; Heidi Christ-Schmidt; Lance Berman; Bertram Pitt
Journal:  N Engl J Med       Date:  2014-11-21       Impact factor: 91.245

Review 6.  Hyperkalemia and potential pitfalls of sodium polystyrene sulfonate.

Authors:  Timothy Nguyen; Daniella Ondrik; Oksana Zhufyak; Watson To; Sining He
Journal:  JAAPA       Date:  2015-03

7.  Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

Authors:  Mikhail Kosiborod; Henrik S Rasmussen; Philip Lavin; Wajeh Y Qunibi; Bruce Spinowitz; David Packham; Simon D Roger; Alex Yang; Edgar Lerma; Bhupinder Singh
Journal:  JAMA       Date:  2014-12-03       Impact factor: 56.272

8.  Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.

Authors:  Bertram Pitt; Stefan D Anker; David A Bushinsky; Dalane W Kitzman; Faiez Zannad; I-Zu Huang
Journal:  Eur Heart J       Date:  2011-01-05       Impact factor: 29.983

9.  A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.

Authors:  Stephen R Ash; Bhupinder Singh; Philip T Lavin; Fiona Stavros; Henrik S Rasmussen
Journal:  Kidney Int       Date:  2015-02-04       Impact factor: 10.612

10.  Characterization of structure and function of ZS-9, a K+ selective ion trap.

Authors:  Fiona Stavros; Alex Yang; Alejandro Leon; Mark Nuttall; Henrik S Rasmussen
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.